Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Bicycle Therapeutics plc BCYC

Healthcare Biotechnology
Bicycle Therapeutics plc is a United Kingdom-based clinical-stage biopharmaceutical company developing a novel class of medicines, referred to as Bicycle molecules, for diseases that are underserved by existing therapeutics. Bicycle molecules are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. The Company is... see more

Recent & Breaking News (NDAQ:BCYC)

Bicycle Therapeutics Announces Further Expansion of Genentech Immuno-Oncology Collaboration

Business Wire July 12, 2022

Bicycle Therapeutics Announces First Patient Dosed in Expansion Cohorts of Phase I/II Trial of Bicycle® Toxin Conjugate BT5528 in Patients with Advanced Solid Tumors Associated with EphA2 Expression

Business Wire June 8, 2022

Bicycle Therapeutics to Participate in the Jefferies Healthcare Conference

Business Wire June 1, 2022

Bicycle Therapeutics to Present Trials in Progress Poster Featuring BT7480 Phase I/II Clinical Trial at the 2022 ASCO Annual Meeting

Business Wire May 26, 2022

Bicycle Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update

Business Wire May 5, 2022

Bicycle Therapeutics Announces Interim BT8009 Phase I Clinical Trial Results at the 2022 AACR Annual Meeting

Business Wire April 11, 2022

Bicycle Therapeutics to Present Interim BT8009 Phase I Clinical Trial Results at the 2022 AACR Annual Meeting

Business Wire April 8, 2022

Bicycle Therapeutics Announces Updated Preclinical Data on SARS-CoV-2 Antivirals at the 2022 Microbiology Society Annual Meeting

Business Wire April 7, 2022

Bicycle Therapeutics to Participate in the 21st Annual Needham Virtual Healthcare Conference

Business Wire April 6, 2022

Bicycle Therapeutics Announces Interim BT8009 Phase I Clinical Trial Results Selected for an Oral Presentation at the 2022 AACR Annual Meeting

Business Wire March 8, 2022

Bicycle Therapeutics to Participate in the Oppenheimer 32nd Annual Healthcare Conference

Business Wire March 8, 2022

Bicycle Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

Business Wire March 1, 2022

Bicycle Therapeutics to Participate at the 11th Annual SVB Leerink Global Healthcare Conference

Business Wire February 9, 2022

Bicycle Therapeutics Announces Continued Clinical Progress and Updates to Management Team

Business Wire January 5, 2022

Bicycle Therapeutics to Participate in Upcoming Investor Conferences

Business Wire November 11, 2021

Bicycle Therapeutics to Present Four Posters Highlighting Preclinical Data from its Bicycle Tumor-Targeted Immune Cell Agonist(TM) (Bicycle TICA(TM)) Programs at the SITC 36th Annual Meeting

Business Wire November 9, 2021

Bicycle Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update

Business Wire November 4, 2021

Bicycle Therapeutics Announces First Patient Dosed in Phase I/II Trial of Bicycle® Tumor-targeted Immune Cell Agonist(TM) BT7480 in Patients with Advanced Solid Tumors Associated with Nectin-4 Expression

Business Wire November 4, 2021

Bicycle Therapeutics Announces Publication of Article Highlighting Preclinical Data from BT7480 Program in the Journal for ImmunoTherapy of Cancer

Business Wire November 2, 2021

Bicycle Therapeutics Announces Expansion of Genentech Immuno-Oncology Collaboration

Business Wire October 26, 2021